Shots:
- The US FDA has accepted sNDA of Kerendia (finerenone) for the treatment of adults with chronic kidney disease (CKD) without diabetes
- sNDA was supported by the P-III (FIND-CKD) trial assessing Kerendia (10 or 20mg) vs PBO, both on top of maximum tolerated labeled doses of a RAS-blocking therapy, in >1,500 adults with non-diabetic CKD
- Trial showed slowed kidney disease progression, reducing the annual eGFR decline by 0.7 mL/min/1.73 m²/year over 32mos. It also reduced the risk of the key CV-kidney composite outcome by 23%, with other 2EPs supporting its overall positive profile
Ref: Businesswire | Image: Bayer | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
